SCHEMBL4705045

SCHEMBL4705045

COc1nc(SCC(=O)N(C)OC)cnc1N(COCC[Si](C)(C)C)S(=O)(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 20/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4699927 0.88 CCR4 (0.36) CCR4
SCHEMBL4699938 0.88 CCR4 (0.39) CCR4
SCHEMBL4701779 0.85 CCR4 (0.35) CCR4
SCHEMBL4703156 0.85 CCR4 (0.36) CCR4
SCHEMBL4705144 0.85 CCR4 (0.34) CCR4
SCHEMBL4700003 0.84 CCR4 (0.37) CCR4
SCHEMBL4701041 0.84 CCR4 (0.37) CCR4
SCHEMBL4700309 0.84 CCR4 (0.38) CCR4
SCHEMBL4705098 0.83 CCR4 (0.36) CCR4
SCHEMBL4756974 0.82 CCR4 (0.35) CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633729-B1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) ASTRAZENECA AB (SE) 2008-07-30 EP disclosed
US-20060122195-A1 Sulphonamide compounds that modulate chemokine receptor activity (ccr4) ASTRAZENECA AB (SE) 2006-06-08 US disclosed
EP-1633729-A1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) AstraZeneca AB (SE) 2006-03-15 EP disclosed
WO-2004108692-A1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) ASTRAZENECA AB (SE) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122195-A1 Sulphonamide compounds that modulate chemokine receptor activity (ccr4) CCR4, CCR1, CCR3 CCR4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.